- Home
- JANX vs IART Comparison
JANX vs IART Comparison
Compare JANX & IART Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- IART
- Stock Information
- Founded
- JANX 2017
- IART 1989
- Country
- JANX United States
- IART United States
- Employees
- JANX N/A
- IART N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- IART Medical/Dental Instruments
- Sector
- JANX Health Care
- IART Health Care
- Exchange
- JANX Nasdaq
- IART Nasdaq
- Market Cap
- JANX 1.4B
- IART 1.2B
- IPO Year
- JANX 2021
- IART 1995
- Fundamental
- Price
- JANX $23.15
- IART $13.60
- Analyst Decision
- JANX Strong Buy
- IART Hold
- Analyst Count
- JANX 11
- IART 8
- Target Price
- JANX $76.55
- IART $18.17
- AVG Volume (30 Days)
- JANX 714.6K
- IART 1.1M
- Earning Date
- JANX 11-05-2025
- IART 11-03-2025
- Dividend Yield
- JANX N/A
- IART N/A
- EPS Growth
- JANX N/A
- IART N/A
- EPS
- JANX N/A
- IART N/A
- Revenue
- JANX $439,000.00
- IART $1,621,738,000.00
- Revenue This Year
- JANX N/A
- IART $5.74
- Revenue Next Year
- JANX $130.50
- IART $4.35
- P/E Ratio
- JANX N/A
- IART N/A
- Revenue Growth
- JANX N/A
- IART 3.53
- 52 Week Low
- JANX $21.73
- IART $11.06
- 52 Week High
- JANX $71.71
- IART $27.13
- Technical
- Relative Strength Index (RSI)
- JANX 48.91
- IART 41.40
- Support Level
- JANX $21.73
- IART $13.73
- Resistance Level
- JANX $24.54
- IART $15.69
- Average True Range (ATR)
- JANX 1.07
- IART 0.68
- MACD
- JANX -0.06
- IART -0.27
- Stochastic Oscillator
- JANX 47.38
- IART 24.79
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About IART Integra LifeSciences Holdings Corporation
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.